阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察

Clinical observation of apatinib combined with chemotherapy for second-line treatment failure in advanced ovarian cancer

目的观察新型靶向药物阿帕替尼联合化疗治疗复发后耐药卵巢癌的近期疗效和安全性。方法选择二线化疗失败的进展期卵巢癌患者30例,按治疗方法分为试验组10例和对照组20例,试验组采用阿帕替尼加紫杉类、蒽环类药物为基础的化疗方案,对照组采用以紫杉类或蒽环类为基础化疗方案化疗,比较2组治疗效果及不良反应发生情况。结果 6个周期后试验组临床疗效优于对照组,客观缓解率和疾病控制率高于对照组,差异均有统计学意义(P<0.05)。不良反应主要为手足综合征、高血压、胃肠胀气及腹泻等,主要为1~2级。结论阿帕替尼联合化疗治疗复发后耐药卵巢癌有较好的疗效,且不良反应可耐受。

Objective To observe the short-term efficacy and safety of the new targeted drug apatinib combined with chemotherapy in the treatment of patients with ovarian cancer recurrence.Methods A total of 30 cases of patients with second-line treatment failure in advanced ovarian cancer were randomly divided into 2 groups:the observation group(n=10)and the control group(n=20).The patients with advanced ovarian cancer adopted a apatinib and taxel,anthracyclines-based combination chemotherapy regimen as observation group.Concurrent other patients who did not receive apatinib were chosen as control group.The therapeutic efficacy and side-effect of the two groups were compare.Results After 6 cycles,clinical curative effect of observation group is better than the control group.There were significant differences in the objective response rate and the disease control rate(P<0.05).The most common adverse reactions were hand-foot syndrome,hypertension,flatulence and diarrhea,mainly in grade 1-2.Conclusion Apatinib combined with chemotherapy is an effective and well-tolerated treatment for advanced ovarian cancer,and the adverse reaction were tolerable.